Naver Backs JNPmedi to Digitize Clinical Trial Data
South Korean internet giant Naver has made a strategic investment in JNPmedi, a developer of eSource and ePRO software for digital clinical trial data capture. The partnership will allow JNPmedi to scale its regulated health IT platform, streamlining workflows for pharmaceutical and biotech clients.
The investment demonstrates the growing interest of tech giants in regulated healthcare platforms, as real-world data becomes increasingly important in drug development. Solutions like JNPmedi’s enhance efficiency and reliability in clinical trials, reducing operational complexity.
For Naver, the investment provides exposure to a high-growth segment of medical technology, while JNPmedi gains capital and strategic support to accelerate product expansion and market reach.
Source:
A.M.
